Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG, with a price target of $50.00.

According to TipRanks, Issi is an analyst with an average return of -5.6% and a 36.64% success rate. Issi covers the Healthcare sector, focusing on stocks such as Moderna, BridgeBio Pharma, and Amgen.

In addition to RBC Capital, Crispr Therapeutics AG also received a Hold from UBS’s Joon Lee in a report issued yesterday. However, on the same day, Piper Sandler reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP).

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $10.18 million and a GAAP net loss of $91.15 million. In comparison, last year the company earned a revenue of $892 thousand and had a GAAP net loss of $208.55 million

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRSP in relation to earlier this year. Most recently, in September 2026, Ali Behbahani, a Director at CRSP sold 13,679.00 shares for a total of $780,934.11.